IL251777A0 - תולדות פיראזול חדשות כמעכבי nik - Google Patents

תולדות פיראזול חדשות כמעכבי nik

Info

Publication number
IL251777A0
IL251777A0 IL251777A IL25177717A IL251777A0 IL 251777 A0 IL251777 A0 IL 251777A0 IL 251777 A IL251777 A IL 251777A IL 25177717 A IL25177717 A IL 25177717A IL 251777 A0 IL251777 A0 IL 251777A0
Authority
IL
Israel
Prior art keywords
pyrazole derivatives
new pyrazole
nik inhibitors
nik
inhibitors
Prior art date
Application number
IL251777A
Other languages
English (en)
Other versions
IL251777B (he
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL251777A0 publication Critical patent/IL251777A0/he
Publication of IL251777B publication Critical patent/IL251777B/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL251777A 2014-10-23 2017-04-19 נגזרות 5–(3–הידרוקסי–פרופינ–1–יל)–3–פיראזול–4–יל)–אינדול כמעכבי nik IL251777B (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14190072 2014-10-23
PCT/EP2015/074433 WO2016062791A1 (en) 2014-10-23 2015-10-22 New pyrazole derivatives as nik inhibitors

Publications (2)

Publication Number Publication Date
IL251777A0 true IL251777A0 (he) 2017-06-29
IL251777B IL251777B (he) 2021-09-30

Family

ID=51865980

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251777A IL251777B (he) 2014-10-23 2017-04-19 נגזרות 5–(3–הידרוקסי–פרופינ–1–יל)–3–פיראזול–4–יל)–אינדול כמעכבי nik

Country Status (13)

Country Link
US (1) US9981962B2 (he)
EP (1) EP3209654B1 (he)
JP (1) JP6616411B2 (he)
KR (1) KR102499862B1 (he)
CN (1) CN107074818B (he)
AU (1) AU2015334916B2 (he)
BR (1) BR112017008039B1 (he)
CA (1) CA2960335C (he)
EA (1) EA033236B1 (he)
ES (1) ES2704749T3 (he)
IL (1) IL251777B (he)
MX (1) MX371150B (he)
WO (1) WO2016062791A1 (he)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
AU2015334914B2 (en) 2014-10-23 2019-09-19 Janssen Pharmaceutica Nv New thienopyrimidine derivatives as NIK inhibitors
BR112017007704B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V Derivados de pirazolopirimidina como inibidores de nik, seu uso e composição farmacêutica que os compreende
JP6616411B2 (ja) 2014-10-23 2019-12-04 ヤンセン ファーマシューティカ エヌ.ベー. 新規な、nik阻害剤としてのピラゾール誘導体
KR102500071B1 (ko) 2014-10-23 2023-02-14 얀센 파마슈티카 엔.브이. Nik 억제제로서의 신규 화합물
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
KR20180094940A (ko) * 2015-12-02 2018-08-24 아스트레아 테라퓨틱스 엘엘씨 피페리디닐 노시셉틴 수용체 화합물
AU2017208555B2 (en) * 2016-01-22 2021-03-18 Janssen Pharmaceutica Nv New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
JP2022534302A (ja) 2019-05-31 2022-07-28 ヤンセン ファーマシューティカ エヌ.ベー. NF-κB誘導キナーゼの低分子阻害剤
TW202402269A (zh) * 2022-05-26 2024-01-16 大陸商迪哲(江蘇)醫藥股份有限公司 ROCK(Rho相關激酶)抑制劑及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510319A (pt) 2004-04-26 2007-10-16 Pfizer inibidores da enzima integrase de hiv
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
AU2009263037B2 (en) * 2008-06-26 2011-10-06 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CA2827161A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
JP6616411B2 (ja) 2014-10-23 2019-12-04 ヤンセン ファーマシューティカ エヌ.ベー. 新規な、nik阻害剤としてのピラゾール誘導体
BR112017007704B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V Derivados de pirazolopirimidina como inibidores de nik, seu uso e composição farmacêutica que os compreende
KR102500071B1 (ko) 2014-10-23 2023-02-14 얀센 파마슈티카 엔.브이. Nik 억제제로서의 신규 화합물
AU2015334914B2 (en) 2014-10-23 2019-09-19 Janssen Pharmaceutica Nv New thienopyrimidine derivatives as NIK inhibitors

Also Published As

Publication number Publication date
JP6616411B2 (ja) 2019-12-04
EP3209654A1 (en) 2017-08-30
BR112017008039B1 (pt) 2023-04-11
US20170334900A1 (en) 2017-11-23
MX2017005283A (es) 2017-08-15
WO2016062791A1 (en) 2016-04-28
JP2017531677A (ja) 2017-10-26
CN107074818A (zh) 2017-08-18
BR112017008039A2 (pt) 2017-12-19
AU2015334916B2 (en) 2020-02-06
EA033236B1 (ru) 2019-09-30
KR102499862B1 (ko) 2023-02-13
CA2960335C (en) 2023-09-19
KR20170068488A (ko) 2017-06-19
MX371150B (es) 2020-01-20
CN107074818B (zh) 2020-04-17
ES2704749T3 (es) 2019-03-19
EA201790904A1 (ru) 2017-08-31
IL251777B (he) 2021-09-30
AU2015334916A1 (en) 2017-03-23
EP3209654B1 (en) 2018-10-03
US9981962B2 (en) 2018-05-29
CA2960335A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
IL287113A (he) מעכבי smyd
HK1223100A1 (zh) 雜環化合物
IL246785A0 (he) בנזאימידאזול–2–אמינים כמעכבי midh1
PL3218378T3 (pl) Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
SI3371190T1 (sl) Heterociklične spojine kot inhibitorji PI3K gama
IL247018A0 (he) תרכובת הטרוציקלית
IL251777A0 (he) תולדות פיראזול חדשות כמעכבי nik
HRP20200133T1 (hr) Novi supstituirani derivati cijanoindolina kao inhibitori nik
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
IL248895A0 (he) מעכבי פוספאתידילינוסיטול 3–קינאז
EP3134408A4 (en) FACTOR XIa INHIBITORS
IL251780A0 (he) תרכובות חדשות כמעכבי nik
EP3148542A4 (en) Factor xia inhibitors
IL251779B (he) תולדות תיאנופירימידין חדשות כמעכבי nik
IL251778B (he) תולדות פיראזולופירימידין חדשות כמעכבי nik
IL285105A (he) תרכובת הטרוציקלית
EP3104701A4 (en) Factor xia inhibitors
EP3180317A4 (en) FACTOR XIa INHIBITORS
EP3180327A4 (en) FACTOR XIa INHIBITORS
EP3104702A4 (en) Factor xia inhibitors
EP3104703A4 (en) Factor xia inhibitors
HK1232227A1 (zh) 作為 抑制劑的喹嗪酮衍生物
EP3180325A4 (en) FACTOR XIa INHIBITORS
IL271808A (he) תולדות אזאינדולין מותמרות חדשות כמעכבי nik
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物